Verastem (NASDAQ:VSTM – Get Free Report) and Biogen (NASDAQ:BIIB – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Valuation and Earnings
This table compares Verastem and Biogen”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Verastem | $30.91 million | 30.21 | -$209.47 million | ($2.05) | -3.61 |
| Biogen | $9.89 billion | 3.75 | $1.29 billion | $2.34 | 107.18 |
Profitability
This table compares Verastem and Biogen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verastem | -178.38% | -359.49% | -78.60% |
| Biogen | 3.37% | 9.38% | 5.69% |
Insider and Institutional Ownership
88.4% of Verastem shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 1.9% of Verastem shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Verastem and Biogen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verastem | 1 | 0 | 11 | 0 | 2.83 |
| Biogen | 1 | 10 | 21 | 1 | 2.67 |
Verastem presently has a consensus target price of $16.83, suggesting a potential upside of 127.17%. Biogen has a consensus target price of $254.41, suggesting a potential upside of 1.44%. Given Verastem’s stronger consensus rating and higher probable upside, equities analysts plainly believe Verastem is more favorable than Biogen.
Volatility and Risk
Verastem has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500.
Summary
Biogen beats Verastem on 9 of the 15 factors compared between the two stocks.
About Verastem
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
About Biogen
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.
